10-Q: Cytek Biosciences Reports 6% Revenue Growth Amidst Rising Costs

Cytek Biosciences announced a 6% increase in total revenue for both the three and six-month periods ending June 30, 2026, reaching $48.1 million and $92.3 million respectively, though net losses also widened.

Summary

• Cytek Biosciences reported a 6% increase in total revenue for the second quarter of 2026 to $48.1 million, and for the first six months of 2026 to $92.3 million, compared to the same periods in 2025.
• Product revenue grew 4% year-over-year for the quarter to $32.6 million and 3% for the six months to $61.3 million.
• Service revenue saw a stronger increase of 10% for the quarter to $15.6 million and 12% for the six months to $30.9 million, driven by an expanding installed base.
• Gross profit margin improved to 59% for the quarter and 54% for the six months, significantly boosted by a $2.8 million tariff refund impacting cost of goods sold.
• Operating expenses increased across the board, with Research & Development up 10% quarterly and 4% semi-annually, Sales & Marketing up 9% quarterly and 1% semi-annually, and General & Administrative expenses up 24% quarterly and 34% semi-annually.
• The company reported a net loss of $12.2 million for the quarter, a significant increase from $5.6 million in the prior year period, and a net loss of $31.0 million for the six months, up from $17.0 million.
• Cash and cash equivalents, along with marketable securities, stood at $262.0 million as of June 30, 2026.
• The company is facing a patent infringement lawsuit from Beckman Coulter, with a trial scheduled for August 17, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed to slightly negative quarter, with revenue growth but increased operating expenses and a widening net loss, despite a positive impact from tariff refunds on gross margin.

Positives

• Total revenue increased by 6% for both the three and six-month periods ended June 30, 2026, reaching $48.1 million and $92.3 million, respectively.
• Service revenue showed robust growth of 10% for the quarter and 12% for the six months, indicating strong recurring revenue potential.
• Gross profit margin improved significantly to 59% for the quarter and 54% for the six months, aided by a $2.8 million tariff refund.
• The company ended the period with a healthy cash and marketable securities balance of $262.0 million.
• Product revenue saw a modest increase of 4% for the quarter and 3% for the six months.

Negatives

• Net loss widened considerably to $12.2 million for the quarter, compared to $5.6 million in the prior year, and to $31.0 million for the six months, compared to $17.0 million.
• Operating expenses increased significantly, particularly General & Administrative expenses, which rose 24% quarterly and 34% semi-annually.
• Research and development expenses increased by 10% for the quarter and 4% for the six months.
• Sales and marketing expenses increased by 9% for the quarter, though only by 1% for the six-month period.
• Excluding the impact of tariff refunds, the product gross margin would have been 52% for the quarter and 48% for the six months, indicating that underlying margins may be under pressure.
• The company is involved in a significant patent infringement lawsuit with Beckman Coulter, with a trial scheduled for August 17, 2026, which could lead to substantial costs and potential liabilities.

Risks

• The company faces a significant patent infringement lawsuit from Beckman Coulter, with a trial scheduled for August 17, 2026, which could result in substantial costs and adverse outcomes.
• Increased operating expenses, particularly in general and administrative areas, are impacting profitability.
• Reliance on single-source suppliers for certain components poses a risk to the supply chain and production.
• The company's financial performance is subject to fluctuations due to the long sales cycles of its instruments and potential seasonality.
• International operations expose the company to various business, regulatory, political, operational, financial, and economic risks.
• Changes in government trade policies, tariffs, and export controls could adversely affect business and results of operations.
• The company's success depends on the adoption of its products by academic and government institutions, and a reduction in their R&D spending could limit demand.
• Competition in the cell analysis and life sciences tools market is intense, and failure to compete successfully could harm revenue and profitability.

Future Outlook

The company expects to continue investing in research and development, commercial infrastructure, and global expansion, which will likely lead to further increases in expenses. Management believes existing cash and cash equivalents will be sufficient to meet working capital and capital expenditure needs for at least the next 12 months.

Management Comments

• We expect our expenses will increase substantially in connection with our ongoing activities, as we attract, hire and retain qualified personnel; invest in processes, commercial infrastructure and supporting functions to scale our business and introduce new products and services; support our research and development efforts; continue to expand geographically; protect and defend our intellectual property; and make strategic investments in complementary businesses, services, products or technologies.
• Our financial performance has largely been driven by our ability to increase the adoption of our FSP platform, a key factor on which our future success depends.
• We believe our expanding installed base of instruments to new and existing customers will provide us with greater leverage to drive pull-through for reagent and service revenue, which are recurring by nature.

Industry Context

StockSavvy.ai notes that Cytek Biosciences operates in the competitive cell analysis and life sciences tools market. The company's revenue growth aligns with broader industry trends of increasing demand for advanced cell analysis solutions, particularly in biomedical research and clinical applications. However, the widening net loss and increasing operating expenses highlight the challenges of scaling in this capital-intensive sector, especially with ongoing R&D investments and competitive pressures.

Comparison to Industry Standards

• Cytek's gross margin of 59% for the quarter (54% YTD), while boosted by tariff refunds, is generally competitive within the life sciences tools sector, where margins can vary significantly based on product mix and scale.
• The company's net loss, however, is a concern. Many companies in this sector, especially those focused on innovation and expansion, experience periods of unprofitability. However, the widening loss suggests that cost control measures may be needed, or that revenue growth needs to accelerate more significantly to offset rising operational costs.
• Competitors like Thermo Fisher Scientific and Danaher (owner of Beckman Coulter) often have higher revenue bases and greater economies of scale, which can translate into more stable profitability and greater R&D investment capacity.

Legal Proceedings

• Beckman Coulter, Inc. filed a patent infringement lawsuit alleging that Cytek's flow cytometers infringe certain patents. A trial is scheduled for August 17, 2026. Cytek denies liability and has filed a counterclaim for false marking.

Stakeholder Impact

• Shareholders: The widening net loss and increased operating expenses, coupled with the ongoing litigation, may negatively impact the stock price and investor confidence.
• Employees: Increased investment in personnel and commercial infrastructure suggests potential for job growth, but rising costs and litigation could create uncertainty.
• Customers: Continued revenue growth and expansion of service offerings are positive, but potential disruptions from litigation or supply chain issues could be a concern.
• Suppliers: The company's reliance on single-source suppliers remains a risk that could impact production and lead times.

Next Steps

• Continue to invest in research and development for new products and solutions.
• Expand commercial infrastructure by hiring additional sales representatives, technical applications specialists, and customer support staff.
• Continue to expand geographically to drive commercialization of products.
• Monitor and manage operating expenses, particularly general and administrative costs.
• Prepare for the upcoming trial in the Beckman Coulter patent infringement lawsuit.
• Continue to leverage the installed base to drive reagent and service revenue.

Key Dates

Recommendation

Cytek Biosciences shows revenue growth and improving gross margins (partially due to one-time benefits), but the significant increase in net loss and operating expenses, combined with ongoing litigation, warrants a cautious 'hold' stance. Investors should monitor cost management and the outcome of the legal proceedings.

Keywords

cell analysis, flow cytometry, Full Spectrum Profiling, FSP technology, biomedical research, clinical applications, instruments, reagents